Photodynamic therapy for age-related macular degeneration

	Treatment Overview
	What To Expect After Treatment
	Why It Is Done
	How Well It Works
	Risks
	What To Think About
	References
	Audio articles:
	English
	Español

Photodynamic therapy (PDT) is a treatment for wet age-related macular degeneration (wet AMD). It is not used to treat dry AMD.

In photodynamic therapy, a light-sensitive medicine called verteporfin (Visudyne) is injected into the bloodstream. The medicine collects in the abnormal blood vessels under the macula. Laser light is then shone into the eye, which activates the medicine and causes it to create blood clots that block the abnormal blood vessels.

By sealing the leaky blood vessels, photodynamic therapy slows down:

• The buildup of fluid under the retina that distorts the shape and position of the macula.
• The growth of scar tissue and the abnormal membrane under the retina, both of which damage the cells in the macula.
• Central vision loss.

Photodynamic therapy takes about 20 minutes and may be done in a doctor's office or eye clinic.

The verteporfin medicine used in PDT makes your skin and eyes more sensitive to light. After treatment, you should avoid direct sunlight for 2 to 5 days and, when outdoors, wear special dark sunglasses to protect your eyes.

Your doctor will want you to return for a follow-up exam about a month after treatment.

Photodynamic therapy is used to treat wet age-related macular degeneration (AMD) only. PDT can only be used for a minority of cases as well.¹

By limiting the growth of abnormal blood vessels under the macula, photodynamic therapy may help prevent the progression of wet AMD. It does not restore vision to eyes that have already been damaged, but it may help prevent further damage to the retina and further vision loss. People with wet AMD often need multiple treatments to get the full benefits of the therapy.

Some experts think that photodynamic therapy may be more effective and less destructive than laser surgery. Laser treatment almost always causes some immediate, permanent central vision loss (a central blind spot), and it does not always prevent future growth of abnormal blood vessels. Photodynamic therapy may be better able to target the blood vessels without damaging the nerve cells in the retina and macula.

PDT can lower the risk of severe vision loss by reducing the growth of and leakage from abnormal blood vessels under the retina.² How well the treatment works depends on where and how the abnormal blood vessels are growing beneath the retina. For some types of wet AMD, the treatment has no detectable benefit.

The effect of PDT in slowing the progress of AMD is often temporary, and the abnormal blood vessels begin leaking again after about 3 months. Most people need multiple treatments to get the full benefits of the therapy.

A severe loss in visual clarity occurs in 1% to 4% of people treated with PDT. In some cases, vision partially recovers.³

Other side effects that may occur with PDT include:

• Temporary visual disturbances (abnormal vision, decreased vision, defects in the visual field).
• Pain, swelling, bleeding, or inflammation at the site where the verteporfin medicine is injected. Some people also experience low back pain related to the injection of the medicine.
• Photosensitivity reactions (such as sunburn).

Photodynamic therapy (PDT) has been shown to be effective for only certain types of wet AMD. The treatment may not work for you.

The effectiveness and long-term consequences of PDT are still being studied.

The verteporfin (Visudyne) dye is an expensive medicine, adding to the overall cost of the treatment. But you must balance this cost against the potential benefit it provides in slowing or reducing the loss of vision from AMD.

Complete the special treatment information form (PDF)(What is a PDF document?) to help you understand this treatment.

Citations

1. Martidis A, Tennant TS (2004). Age-related macular degeneration. In M Yanoff et al., eds., Ophthalmology, 2nd ed., pp. 925–933. St. Louis: Mosby.

2. Arnold J (2006). Age-related macular degeneration, search date March 2005. Online version of Clinical Evidence (15).

3. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group (2001). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of two randomized clinical trials—TAP report 2. Archives of Ophthalmology, 119(2): 198–207.